Adagene
Manufacturing · China · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Building C14 Xinghu Street Suzhou Indust...Phone Number
+86 51287773632Website
www.adagene.comRevenue
<$5 MillionStock Symbol
ADAGIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Adagene
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China.Explore more
Adagene Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Adagene your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Adagene has new funding data
Website visits: Recent activity has been detected on your website
Check out if Adagene is spiking on competitors!
Click to see if Adagene had a recent Job posting/layoffs
Adagene, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Adagene has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Adagene recently announced quarterly report
Product Launch: Get notified when Adagene launches new products
Congratulate Masked Content for being promoted to Masked Content at Adagene
Recommended Actions
Find VP level buyers at Adagene
Find 2 more new buyers
Company Profile Activity
Activity Insights
Adagene is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Adagene is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Adagene.
Adagene financials insights
Gather financial insights about Adagene, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$8M
2016
Series B
$28M
2018
Series C
$50M
2020
Series D
$69M
2021
Stock Offering
$140M
2025
Other Financing Round
$25M
Adagene Tech Stack
A closer look at the technologies used by Adagene
See more technologies
Most Recent Scoops
Person-Based
Earnings, Funding, Finance
Open Position
Open Position
Project
Adagene has stated publicly that enrollment for the randomized phase II trial should be completed before the end of this year.
Pharmaceuticals, Clinical Operations
Project
Product Development, Bioengineering, Pharmaceuticals
Adagene News & Media
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has been establishedAdagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer
Adagene (NASDAQ:ADAG) Chief Strategy Officer Mickael Chane-Du outlined the company’s clinical strategy for its lead antibody program, ADG126, during a discussion with Stifel senior biotech analyst Stephen Willey, emphasizing the company’s focus on improving the therapeutic index of CTLA-4 inhibitionAdagene to Participate in Two Upcoming Investor Conferences
SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in one-on-one investor meetings and a fireside chat at the Stifel Annual Virtual Oncology Event on May 19-20, 2026 and one-on-one investor meetings at the Jefferies LLC Global Healthcare Conference being held June 2-4, 2026 in New York, NAdagene (ADAG) Partners With Incyte (INCY) to Evaluate Combination Therapy for Colorectal Cancer
Adagene Inc. (NASDAQ:ADAG) is one of the 10 Unstoppable Stocks That Could Double Your Money. Adagene Inc. (NASDAQ:ADAG) is one of the unstoppable stocks that could double your money. On April 2, Adagene announced a clinical collaboration with Incyte Corp. (NASDAQ:INCY) to evaluate a novel combination therapy for microsatellite stable colorectal cancer/MSS CRC. The study […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Adagene
Sign Up For FreeTo access detailed company insights
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China.... Read More
